RespireRx Pharmaceuticals Inc. (RSPI) has been involved in several key activities and updates in 2024:
Cannabinoid Confusion: There has been ongoing debate and confusion in the U.S. regarding cannabinoids. Despite this, RSPI’s Australian deal is considered financially sensible, although there has been no recent update on this matter.
Preclinical Progress: It is assumed that preclinical work with new formulations is in progress, but there has been no update on any FDA discussions or additional funding for their development path.
Drug Platforms: RSPI’s filings have suggested that all their drug programs should be partnered, joint-ventured, or sold. The status of one of the three main platforms could significantly impact the other two.
OSA Drug Development: For the OSA drug, RSPI is awaiting the manufacture of new formulations. With roughly half of the funding in place and intent to list on the ASX, they are a few steps away from clinical trials with the new formulations.
Clinical Trials for Other Candidates: The recent PR suggests that trials for the spinal and ADHD candidate might occur later this year, pending funding. The epilepsy/pain candidate drug is in tier 3 of NIH, and the CEO has indicated a short-term goal of securing funds to support it.
Stock Performance: There has been mention of dilution, but shares are considered tight as investors are believed to be absorbing available shares in numbers.
These updates reflect RSPI’s ongoing efforts in drug development and its strategic moves in the pharmaceutical industry. The company seems to be progressing towards clinical trials for its new formulations and seeking partnerships to advance its drug candidates.
